Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy

被引:74
作者
Bossi, Gianluca [1 ]
Marampon, Francesco [2 ]
Maor-Aloni, Revital [3 ]
Zani, Bianca [2 ]
Rotter, Varda [3 ]
Oren, Moshe [3 ]
Strano, Sabrina [1 ,4 ]
Blandino, Giovanni [1 ,4 ]
Sacchi, Ada [1 ]
机构
[1] Regina Elena Inst Canc Res, Dept Expt Oncol, I-00158 Rome, Italy
[2] Univ LAquila, Dept Expt Med, Laquila, Italy
[3] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
[4] Regina Elena Inst Canc Res, Rome Oncogen Ctr, I-00161 Rome, Italy
关键词
mutant p53; gain of function; conditional RNAi; in vivo studies; molecular targets;
D O I
10.4161/cc.7.12.6161
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness. Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded. To address this point, mimicking more physiological conditions, we now describe the establishment of a lentiviral-based system for conditional interference with mutant p53 expression. In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability. Moreover by using this system, microarray data were validated in vitro and in vivo and putative mutant p53 target genes that may contribute to its gain of function effects in cancer were identified. Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
引用
收藏
页码:1870 / 1879
页数:10
相关论文
共 40 条
  • [11] The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis
    Fontijn, RD
    Goud, B
    Echard, A
    Jollivet, F
    van Marle, J
    Pannekoek, H
    Horrevoets, AJG
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (08) : 2944 - 2955
  • [12] Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain
    Frazier, MW
    He, XP
    Wang, JL
    Gu, ZM
    Cleveland, JL
    Zambetti, GP
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (07) : 3735 - 3743
  • [13] FUKUMOTO Y, 1990, ONCOGENE, V5, P1321
  • [14] GREEVE I, 2000, J NEUROSCI, V63, P111
  • [15] Hainaut P, 2000, ADV CANCER RES, V77, P81
  • [16] The p53 pathway: positive and negative feedback loops
    Harris, SL
    Levine, AJ
    [J]. ONCOGENE, 2005, 24 (17) : 2899 - 2908
  • [17] Differential analysis of DNA microarray gene expression data
    Hatfield, GW
    Hung, SP
    Baldi, P
    [J]. MOLECULAR MICROBIOLOGY, 2003, 47 (04) : 871 - 877
  • [18] A role for JNK-paxillin signaling in cell migration
    Huang, C
    Jacobson, K
    Schaller, MD
    [J]. CELL CYCLE, 2004, 3 (01) : 4 - 6
  • [19] Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease
    Iivonen, S
    Hiltunen, M
    Alafuzoff, I
    Mannermaa, A
    Kerokoski, P
    Puoliväli, J
    Salminen, A
    Helisalmi, S
    Soininen, H
    [J]. NEUROSCIENCE, 2002, 113 (02) : 301 - 310
  • [20] The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling
    Jin, K
    Lim, S
    Mercer, SE
    Friedman, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (51) : 42097 - 42105